Microorganisms have made considerable contributions to the production of peptide secondary metabolites, many of them with therapeutic potential, e.g., the fungus-derived immunosuppressant cyclosporine A and the antibiotic daptomycin originating from Streptomyces. Most of the medically used peptides are the product of non-ribosomal peptide synthetases (NRPS), incorporating apart from proteinogenic also unique, non-proteinogenic amino acids into the peptides. An extremely rare such amino acid is 3-(3-furyl)-alanine. So far, only few peptides have been found that contain this residue, including the rhizonins, bingchamide B and endolides. The producer of the rhizonins was proven to be the bacterial endosymbiont Burkholderia endofungorum inside the fungus Rhizopus microsporus. The microbial origin, chemistry and bioactivity of the 3-(3-furyl)-alanine containing peptides are the focus of this review.
Among the huge class of secondary metabolites, peptides are a restricted group of structurally diverse compounds produced by prokaryotes like bacteria, and eukaryotes, e.g. fungi [1] . They are often essential for the survival and growth of the microbial producers in the rivalry of their natural habitat, acting as siderophores, toxins or signaling molecules [2] . Many of these peptides have important medical applications as antibiotics, e.g., daptomycin, and immunosuppressants, e.g., cyclosporine A [3] . In terms of biosynthesis, some of these peptides originate from ribosome-derived precursor molecules and gain their final structure by post-translational modifications, e.g., microcins, microviridins and polytheonamides [4] . A second group of these peptides, including most of the medically used ones, are produced by nonribosomal peptide synthetases (NRPS), which function as multimodular enzymes connecting small building blocks, predominantly amino acids, but in some cases also carboxy acids [5] . The latter group often contains unique, non-proteinogenic amino acids, such as hydroxyphenylglycines in vancomycin and (4R)-4-[(E)-2butenyl]-4-methyl-L-threonine in cyclosporine A [2] . Over 500 different amino acids are known to date, either found as partial structures in peptides, as free low molecular weight natural products, or are metabolic intermediates [6] . 3-(3-Furyl)-alanine (1) is such a non-proteinogenic, heterocyclic amino acid incorporated in non-ribosomal peptides, but to date not encountered free in nature ( Figure 1 ). In contrast, the 3-(3-furyl)-alanine carboxy derivative, L-3-(3-carboxyfuran-4-yl)-alanine (2) was isolated from the fruiting bodies of the gilled non-edible mushrooms Phyllotopsis nidulans and Tricholomopsis rutilans ( Figure 1) [7, 8] . For this component no biological activity has been described to date. Chemically synthesized L-3-(3-furyl)-and L-3-(2-furyl)-alanine, however, exhibit growth inhibitory activity towards both bacteria and fungi [9] , making them potentially useful agrochemical fungicides, industrial microbicides and wood preservatives [10] .
3-(3-Furyl)-alanine as a building block in bioactive natural products:
Even though 3-(3-furyl)-alanine is so far not known as an unbound amino acid, fungi and bacteria incorporate this residue into peptide structures with diverse bioactivities (Figure 2 , Table 1 ). Endolide B (7) Affinity to the vasopressin receptor 1A (K i = 7.04 µM) [19] Affinity to the serotonin receptor subtype 5HT 2b (K i = 0.77 µM) [19] The first described naturally occurring peptides containing 3-(3furyl)-alanine were rhizonin A (3) and B (4), at that time isolated from Rhizopus microsporus, a fungus used to prepare fermented food [11] . Interestingly, the two 3-(3-furyl)-alanine units in rhizonin A possess opposite absolute configurations as determined from Xray crystallography. The rhizonins were regarded as the first mycotoxins isolated from fungi (Zygomycota), with most known mycotoxin producing strains belong to the fungal phyla Ascomycota or Basidiomycota [12] . It was later found that the true producer of rhizonins is in fact the bacterial endosymbiont Burkholderia endofungorum, which resides inside the fungal cytosol [13] . This was also true for the polyketide-derived antimitotic macrolide rhizoxin, initially believed to be a product of R. microsporus but later discovered to be produced by Burkholderia rhizoxinica [14] . Rhizonin A exhibited potent hepatotoxic effects in rats [15] , and cytotoxicity, which was mainly ascribed to its 3-(3-furyl)-alanine partial structure. Synthetic replacement of this moiety with phenylalanine gave analogues 8 and 9 with reduced cytotoxicity and NPC Natural Product Communications 2017 Vol. 12
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improved in vitro fat-accumulation inhibitory activity in 3T3-L1 murine adipocytes [16] . Controversially, rhizonin A showed plant growth promoting activity in lettuce seed germination, and thus, the rhizobacterial strain Burkholderia sp. KCTC11096 is to be explored for supporting sustainable agricultural production [17] .
The second report of a 3-(3-furyl)-alanine building block is related to the cyclic pentapeptide, bingchamide B (5), isolated from a soildwelling strain of Streptomyces bingchenggensis [18] . The absolute configuration of the amino acid building blocks of bingchamide B, including 3-(3-furyl)-alanine, was not determined. Bingchamides exhibited in vitro cytotoxic activity towards human colon cancer cell line HCT-116 with an IC 50 value of 18 µg mL -1 for bingchamide B and an IC 50 value of 14.1 µg mL -1 for its natural analogue bingchamide A (10), featuring a phenylalanine residue in place of the 3-(3-furyl)-alanine [18] . Recently, the novel tetrapeptides endolide A (6) and B (7) were isolated from a solid culture of the marine sponge-derived fungus Stachylidium sp. [19] . Here, the two 3-(3-furyl)-alanine units in endolide A were assigned the L-configuration as determined from X-ray crystallography and Marfey's analysis. Hitherto the endolides were regarded as the first fungal peptides containing 3-(3-furyl)alanine. Whether the endolides are presumably produced by an endofungal bacterium, as in the case of rhizonins, could not be unequivocally proven, as it was not yet possible to isolate and culture axenic bacteria from the Stachylidium sp. fungus [19] .
Unlike the other 3-(3-furyl)-alanine containing peptides rhizonin A and bingchamide B, the endolides did not exhibit any in vitro cytotoxicity. Interestingly, they have affinity to G protein-coupled receptors (GPCRs) in radioligand binding assays. Endolide A showed affinity to the vasopressin receptor 1A with a K i of 7.04 µM, while endolide B had selective affinity to the serotonin receptor subtype 5HT 2b with a K i of 0.77 µM [19] .
A structural analogue of the endolides, hirsutide (11) , was isolated from the entomopathogenic fungus Hirsutella sp. Hirsutide features phenylalanine residues instead of the 3-(3-furyl)-alanine residues in endolide B [20] . Initially no bioactivities were reported for hirsutide. However, its recent chemical synthesis and detailed pharmacological screening revealed potent antibacterial activity against the Gram-negative bacteria Pseudomonas aeruginosa and Klebsiella pneumoniae, with additional anthelmintic activity and minor cytotoxic effects against Dalton's lymphoma ascites and Ehrlich's ascites carcinoma cell lines with IC 50 values of 14 and 22 µM, respectively [21] .
Putative biosynthesis of peptides and 3-(3-furyl)-alanine:
Peptide secondary metabolites are assembled either through the ribosomal machinery, i.e., through direct gene translation [4] , or by multi-modular non-ribosomal peptide synthetases (NRPS) [2] . In the translation system, decoding of the trinucleotide sequence (codon) information stored in the messenger RNA determines the peptide amino acid sequence. Here each codon assigns a single amino acid from the known pool of 20 L-configured proteinogenic amino acids [22] .
On the other hand, NRPS assembly lines are divided into modules termed initiation and elongation modules, where each module is responsible for integrating a dedicated substrate into the growing peptide chain. This is done with the help of catalytic domains, a sub-division of each module. Fundamental domains are indispensable for the selection and activation of the building blocks (adenylation, A-domain), the tethering of the product to the enzyme (peptidyl carrier protein, PCP-domain) and peptide bond formation (condensation, C-domain). Structural diversity arises due to the presence of auxiliary domains imparting unique structural features to the non-ribosomal peptides. These include epimerization (E) domains for incorporating D-amino acids, methylation (Mt) domains for introducing methyl groups and oxidation (Ox) and reduction (R) domains for the formation of heterocyclic rings. Finally, a terminal thioesterase (TE) domain catalyzes peptide release and at times cyclization [23] .
A closer look into the structural architecture of the rhizonins, bingchamides and endolides proposes a non-ribosomal biosynthetic origin. This is implied due to the incorporated amino acid residues, i.e., N-methylated, sometimes D-configured, and structurally unusual non-proteinogenic in nature, i.e., 3-(3-furyl)-alanine. For the rhizonins, total DNA isolated from the cultured B. endofungorum afforded NRPS gene fragments. However, the exact NRPS genes involved in the biosynthesis of rhizonins were not yet revealed and further studies are underway [13] . Analysis of the S. bingchenggensis genome yielded gene clusters postulated to encode NRPSs. These include modules with adenylation domain substrate specificities, correlating with the structures of bingchamides [24] . However, no proof for a responsible biosynthetic gene cluster is currently available.
In NRP biosynthesis, not only the multi-modular NRPS assembly line is of importance, but also the formation of the building blocks.
Often the respective enzymes are encoded as part of or adjacent to
The rare amino acid building block 3-(3-furyl)-alanine Natural Product Communications Vol. 12 (1) 2017 149 the biosynthetic gene cluster [25, 26] . So far, no biosynthetic studies were conducted to reveal the biosynthetic origin of 3-(3-furyl)alanine, apart from it being considered a potential substrate for the NRPS biosynthetic machinery. Taking known biosynthetic pathways for similar furans into consideration, several pathways for 3-(3-furyl)-alanine may be proposed here.
A furan ring as such is encountered in many secondary metabolites. In terpenoids, furan ring biosynthesis utilizes active isoprene units, i.e., isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), as seen in the diterpenoids divinatorins (12) and bibifuran (13) [27, 28] . The signaling molecules methylenomycin furans (MMFs) (14) and the furanylcarbonyl containing acyl rhamnosides (15) are formed by a mixed acetate-glycerol pathway [29] [30] [31] [32] . The latter involves the condensation of a dihydroxyacetone-derived three-carbon unit originating from glycerol and a β-ketothioester intermediate derived from a polyketide synthase or fatty acid metabolism ( Figure 5 ). In contrast, the hydroxyfuranone (16) and methoxyfuranone (17) , volatile strawberry aroma compounds, are obtained from carbohydrate metabolism, i.e., from D-fructose [33] . However, the association of the furan skeleton with an amino acid, i.e., alanine, implies other precursor molecules to be involved in its biosynthesis. 3-(3-Furyl)-alanine is an analog of the shikimatederived aromatic amino acid phenylalanine [34] . Thus, the structural relationship between the 3-(3-furyl)-alanine and the phenylalanine skeleton, may point to the possibility of furyl-alanine being formed by ring cleavage of a phenylalanine intermediate. Such a ring cleavage is known for several metabolites such as the mycotoxin patulin [35] , the betalain plant pigments [36] , and pyrrolobenzodiazepine anti-tumor antibiotics [37] . Feeding of isotopically labeled phenylalanine to the respective microbial cultures could clarify this presumption.
On the other side however, the unique dihydrofuranacrylic acid moiety of the antibiotic reductiomycin (18), a Streptomyces metabolite, also shares the basic carbon skeleton with 3-(3-furyl)alanine [38] . In this case, labeling studies showed that the dihydrofuranacrylic acid moiety is derived from a symmetrical product of the shikimate pathway, i.e., p-hydroxybenzoic acid, by aromatic ring cleavage ( Figure 6 ) [39] . Figure 6 : Biosynthesis of the dihydrofuranacrylic acid moiety of reductiomycin via the shikimate pathway, adopted from literature [38, 39] . Cleavage occurs either at site A, or alternatively at B, resulting in different isotope labeling patterns (not shown here).
Which metabolic pathway underlies the biosynthesis of the unique 3-(3-furyl)-alanine moiety in the peptides, and whether all the peptides incorporating such a moiety have a similar biosynthetic origin is yet to be revealed.
Conclusion:
Microorganisms have made considerable contributions to the production of peptide secondary metabolites, many of them with therapeutic potential, e.g., the immunosuppressant cyclosporine A [40] and the antibiotic daptomycin [41] . Indeed, peptides that occur in nature as secondary metabolites share structural features like a cyclic architecture, N-methylation of amide bonds, and incorporation of atypical building blocks, such as Damino acids, carboxy acids and non-proteinogenic amino acids. Such features bestow several attractive attributes in terms of receptor affinity and selectivity and improved proteolytic stability, making them interesting drug scaffolds [3] . With the ongoing interest in peptide-based drugs [42] , 3-(3-furyl)-alanine containing peptides add an interesting structural variation to this group of natural products. However, a deeper understanding of their biosynthesis and bioactivities should be sought, in order to be implemented in the drug-design process.
